Learning Meta-Descriptions of the FOAF Network

Postprin

Comparación de metodologías para la purificación de proteínas de membrana externa de Brucella abortus.

Las proteínas de la membrana externa de la Brucella abortus, Cepa 19 y RB-51 se purificaron por dos métodos, el primero basado en la extracción secuencial por tratamientos sucesivos con detergentes y lisozima y el segundo, en la formación del saco de peptidoglican con sus proteínas asociadas, utilizando dodecil sulfato de so-dio (SOS) a 50°C y extracción directa de las proteínas de la membrana externa con 50 mM de MgCl2 en SDS-23 Mercaptoetanol a 37°. Se utilizó la sonicacion para lograr la ruptura bacterial y su efecto se comprobó por microscopia electrónica. Las proteínas obtenidas se caracterizaron por electroforesis en geles de poliacrilamida. El método de extracción por detergentes aniònicos débiles y dipolares y tratamiento con lisozima, comprobó ser superior en calidad, selectividad y concentración de las proteínas de interés. Los pesos moleculares obtenidos para las proteínas denominadas porinas van de 37 a 41 kilo Daltons (k0), asi mismo se detecta una proteína de bajo peso molecular (14kI3). Se detecto reacción especifica de las proteínas en sueros controles de bovinos con infección natural de B. abortus por to técnica de inmunotransferencia en papel de nitrocelulosa.Outer membrane proteins of Bruce/la abortus strain 19 and strain RB-51 were purified using two methods. One based on sequential detergent extraction plus iysosyme treatment and the other obtaining peptidoglican saculae associated proteins by sodium dodecil sulfate (SDS) treatment at 50°C, and external protein extraction with SDS-23 mercaptoetanol, 50 mM MgCl2 at 37°C. Sonication was used in order to disrupt the cells and its effect was monitored by electron microscopy. The proteins were characterized by polycrilamide gel electrophoresis. Detergent and lysozyme treatment demonstrated superiority over SDS extraction regarding selectivity, antigenicity and yield. The proteins obtained from strain RB-51 had less LPS contamination. The molecular weights of the porin proteins obtained ranged between 37 and 41 kD, and a 14 kD protein was also detected. Specific reaction of the purified proteins was detected by western-blotting with positive bovine control serums.Ganado de leche-Ganadería lech

In Situ Synthesis of Al-Based MMCs Reinforced with AlN by Mechanical Alloying under NH3 Gas

Aluminum matrix composites (AMCs) reinforced by aluminum nitride were prepared by mechanical alloying followed by a simple press and sintering method. Milling began under vacuum and after a period of between 1 and 4 h, NH3 gas flow (1 cm3/s) was incorporated until the total milling time of 5 h was reached. Results show that in addition to the strain hardening taking place during mechanical alloying, NH3 plays an additional role in powder hardening. Thereby, the properties of the sintered compacts are strongly influenced by the amount of N incorporated into the powders during milling and the subsequent formation of AlN during the consolidation process. The obtained AMC reaches tensile strengths as high as 459 MPa and hardness much higher than that of the as-received aluminum compact.Financial support of the Ministerio de Economia y Competitividad (MINECO/FEDER, Spain) through the research project DPI2015-69550-C2-1-P is gratefully acknowledged

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

<p>Abstract</p> <p>Background</p> <p>The presence of IgG antibodies to HPV-16 L1-virus like particles (VLPs) in serum has been reported as a result of persistent exposure to the virus and as a marker of disease progression. However, detection of VLP-specific antibodies in sera does not always indicate a malignant lesion as positive results may also be due to a nonmalignant viral infection. Furthermore, malignant lesions are associated with an increased antibody titer for E6 and E7 proteins. The aim of this study was to develop an ELISA using a novel chimeric virus-like particle (cVLP) encoding an L1 protein fused with a string of HPV-16 E6 and E7 seroreactive epitopes to its C-terminus to be used for detection of HPV-16 specific antibodies in patients with cervical intraepithelial lesion grade 1 (CIN 1).</p> <p>Results</p> <p>The sera of 30 patients with CIN 1 who also tested positive for HPV-16 DNA and of 30 age-matched normal donors negative for HPV infection were tested for the presence of IgG antibodies specific for either VLP-L1 (HPV-16 L1), gVLP (derived from Gardasil), or cVLP by ELISA. The cVLP-reactive sera yielded two distinct groups of results: (H) reactivity levels that presented very strong cVLP-specific titers, and (L) reactivity levels with significantly lower titers similar to those obtained with VLP-L1 and gVLP antigens. Additionally, the sera that presented the higher cVLP titers closely matched those that had significantly stronger reactivity to E6 and E7 epitopes. Interestingly, the samples with the highest titers corresponded to patients with the higher numbers of sexual partners and pregnancies. On the other hand only 4 out of the 12 sera that harbored antibodies with VLP neutralizing ability corresponded to the group with high cVLP antibody titers.</p> <p>Conclusion</p> <p>We report for the first time that chimeric particles containing HPV-16 L1 protein fused with E6 and E7 seroreactive epitopes enable much better detection of IgG antibodies in the sera of CIN 1 patients positive for HPV-16 infection than those obtained with VLPs containing only the HPV-16 L1 protein. We also found that the sera with higher cVLP antibody titers corresponded to patients with more sexual partners and pregnancies, and not always with to those with a high neutralizing activity. This novel assay could help in the development of a tool to evaluate cervical cancer risk.</p

Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART) : study protocol

Altres ajuts: RETICS funded by the PN 2018-2021 (Spain).Congenital heart disease (CHD) is the most prevalent congenital malformation affecting 1 in 100 newborns. While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. Eligible participants are women presenting at 20 to < 37 weeks of gestation carrying a fetus with CHD. Maternal/neonatal recordings are performed at regular intervals, from the fetal period to 24 months of age, and include: placental and fetal hemodynamics, fetal brain magnetic resonance imaging (MRI), functional echocardiography, cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers. Neurodevelopmental assessment is planned at 12 months of age using the ages and stages questionnaire (ASQ) and at 24 months of age with the Bayley-III test. Target recruitment is at least 150 cases classified in three groups according to three main severe CHD groups: transposition of great arteries (TGA), Tetralogy of Fallot (TOF) and Left Ventricular Outflow Tract Obstruction (LVOTO). The results of NEURO-HEART study will provide the most comprehensive knowledge until date of children's neurologic prognosis in CHD and will have the potential for developing future clinical decisive tools and improving preventive strategies in CHD. , on 4th December 2016 (retrospectively registered)

Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART): study protocol.

BACKGROUND: Congenital heart disease (CHD) is the most prevalent congenital malformation affecting 1 in 100 newborns. While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. METHODS: Eligible participants are women presenting at 20 to < 37 weeks of gestation carrying a fetus with CHD. Maternal/neonatal recordings are performed at regular intervals, from the fetal period to 24 months of age, and include: placental and fetal hemodynamics, fetal brain magnetic resonance imaging (MRI), functional echocardiography, cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers. Neurodevelopmental assessment is planned at 12 months of age using the ages and stages questionnaire (ASQ) and at 24 months of age with the Bayley-III test. Target recruitment is at least 150 cases classified in three groups according to three main severe CHD groups: transposition of great arteries (TGA), Tetralogy of Fallot (TOF) and Left Ventricular Outflow Tract Obstruction (LVOTO). DISCUSSION: The results of NEURO-HEART study will provide the most comprehensive knowledge until date of children's neurologic prognosis in CHD and will have the potential for developing future clinical decisive tools and improving preventive strategies in CHD